Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

9 Pages (Click to Jump) V  < 1 2 3 4 5 6 > »    
 
  
Reply to this topic

RMD, RESMED INC
arty
post Posted: Oct 13 2009, 08:11 PM
  Quote Post


Posts: 13,078
Thanks: 3381


It's been some time that RMD attracted any interest. wacko.gif Strange ... considering the posts lavished on other stocks ...

Today's price and volume action can't remain unnoticed. Are we on course for a new High?
When Trinity fired in June and August, those signals were defintely followed by tradeable advances. This time, even the volume is sufficient to tick the third box for a green signal.

Attached Image



Where does the chart come from? The Weekly chart shows the turnaround in early June rated even an "investment-grade" move into mid-August; the ensuing consolidation could be interpreted as a "buy-the-dip" opportunity. Still not too late even for that?

Maybe Spicy Posh can make a song and dance about it wub.gif

Attached Image





--------------------
I trade daily, but I am not a licensed adviser. Whether you find my ideas reasonable or not: The only person responsible for your actions is YOU.
I follow two rules: (1) There are no sacred truths. All assumptions must be critically examined. Arguments from authority are worthless. (2) Whatever is inconsistent with observed facts must be discarded or revised. We must understand the Market as it is and not confuse how it is with how we wish it to be. (inspired by Carl Sagan)
 
dan.heath
post Posted: May 11 2009, 06:38 PM
  Quote Post


Posts: 685
Thanks: 5


Still like this performance . I underlined the part I like.


RESMED INC. ANNOUNCES RECORD FINANCIAL RESULTS FOR THE

QUARTER AND NINE MONTHS ENDED MARCH 31, 2009

SYDNEY, Australia, May 8, 2009 - ResMed Inc. (ASX: RMD) today announced record revenue and income for the quarter ended March 31, 2009. Revenue for the March 2009 quarter was US$227.9 million, an 8% increase (a 16% increase on a constant currency basis) over the quarter ended March 31, 2008. For the quarter ended March 31, 2009, income from operations was US$52.5 million and net income was US$39.2 million, an increase of 40% and 32%, respectively, compared to the quarter ended March 31, 2008. Diluted earnings per share for the quarter ended March 31, 2009 were US$0.51, an increase of 34% compared to the quarter ended March 31, 2008.



 
hungry
post Posted: Mar 26 2009, 01:46 PM
  Quote Post


Posts: 2,967
Thanks: 271


Might be having a reversal today following the sector bounce. Macd bullish divergence is in on the dly.

 
dan.heath
post Posted: Feb 7 2009, 10:11 PM
  Quote Post


Posts: 685
Thanks: 5


RESMED INC ANNOUNCES RECORD FINANCIAL RESULTS FOR THE

QUARTER AND SIX MONTHS ENDED DECEMBER 31, 2008

SYDNEY, Australia, February 6, 2009 - ResMed Inc. (ASX: RMD) today announced record revenue and income for the quarter ended December 31, 2008. Revenue for the December 2008 quarter was US$223.0 million, a 10% increase (a 16% increase on a constant currency basis) over the quarter ended December 31, 2007. For the quarter ended December 31, 2008, income from operations was US$43.3 million and net income was US$33.9 million, an increase of 18% and 26%, respectively, compared to the quarter ended December 31, 2007. Diluted earnings per share for the quarter ended December 31, 2008 were US$0.44, an increase of 29% compared to the quarter ended December 31, 2007.

SG&A expenses were US$70.1 million for the December 2008 quarter, an increase of US$2.4 million or 4% (a 14% increase on a constant currency basis) over the same period in fiscal 2007. SG&A expenses were favorably impacted by the appreciation of the U.S. dollar against international currencies. This increase in SG&A was primarily due to expenses necessary to support sales growth. SG&A costs were 31% of revenue in the December 2008 quarter, compared to 33% in the same period in fiscal 2007.

R&D expenses were US$14.9 million for the December 2008 quarter, or approximately 7% of revenue. R&D expenses were flat (a 27% increase on a constant currency basis) compared to the prior year quarter. R&D was also positively impacted by the appreciation of the U.S. dollar against international currencies, particularly the Australian dollar. Research and development outlay reflects ResMed’s continuing commitment to innovation within its product portfolio, as well as an ongoing commitment to clinical research and product development.

Amortization of acquired intangibles of US$1.7 million (US$1.1 million net of tax) incurred during the quarter ended December 31, 2008, consisted of amortization of assets associated with our acquisitions of Resprecare, Hoefner, Saime and PolarMed. Stock-based compensation costs incurred during the quarter ended December 31, 2008 of US$6.8 million (US$4.9 million net of tax) consisted of expenses associated with stock options granted to employees and our employee stock purchase plan.

During the December 2008 quarter, we donated US$1.0 million (US$0.6 million, net of tax) to the ResMed Foundation. The Foundation was established primarily to promote research into the deleterious medical consequences of untreated sleep-disordered breathing.

For the six months ended December 31, 2008 revenue was US$440.9 million, an increase of 14% over the six months ended December 31, 2007. For the six months ended December 31, 2008, income from operations and net income were US$79.9 million and US$61.9 million, an increase of 16% and 21%, respectively, compared to the six months ended December 31, 2007. Diluted earnings per share for the six months ended December 31, 2008 were US$0.80 per diluted share, an increase of 23% compared to the six months ended December 31, 2007.

Inventory, at US$143.1 million, decreased by US$15.2 million compared to June 30, 2008. Accounts receivable days sales outstanding, at 76 days, increased by 4 days compared to June 30, 2008.

Kieran T. Gallahue, President and Chief Executive Officer, commented, "In the second quarter of fiscal 2009, we continued to show strong growth year over year. Sales in the Americas totaled US$123.1 million, a 23% increase over the prior year quarter while sales outside the Americas were US$99.9 million, a decrease of 3% over the prior year quarter. As expected, sales outside of the Americas were impacted by currency movements, in particular the depreciation of the Euro against the U.S. dollar. In constant currency terms, sales outside of the Americas increased by 8% over the prior year quarter. Cash flow from operations for the December 2008 quarter was a very strong US $56.5 million.

"Our new product cycle remains in full swing as we launched a number of new products during the second quarter. In the mask category, we launched the Activa LT, which offers patients superior performance, yet is quieter and less obtrusive. We also launched the Swift LT for Her, our first gender-specific product, targeted at the rapidly growing female segment of the therapy market. Our VPAP product line continues to gain momentum with the release of the complete family of bilevel devices in the smaller S8 box. Looking forward, our pipeline of products scheduled for release over the next 18 months remains full and demonstrates our ongoing commitment to bringing innovative technologies to market across both the mask and flow generator product lines.

"We were also very encouraged to see gross margin expand in Q2. We expect continued improvement over the course of fiscal 2009 as we benefit from accelerating sales of our high margin masks and VPAP products, continuing efforts to leverage cost efficiencies across our global organization and the depreciation of the Australian dollar. We remain well positioned to execute our strategy of introducing innovative new products and driving adoption of sleep-disordered breathing therapies in this rapidly growing global market."

ResMed

ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

ResMed will host a conference call at 8:30 a.m. Australian Eastern Daylight Time (AEDT) today to discuss these quarterly results. Individuals wishing to access the conference call may do so via ResMed's Website at www.resmed.com or by dialing +1 (617) 847-8712 and entering conference I.D. No. 28551812. Please allow extra time prior to the call to visit the Web site and download the streaming media player (Windows Media Player) required to listen to the Internet broadcast. The online archive of the broadcast will be available approximately 90 minutes after the live call and will be available for two weeks. A telephone replay of the conference call is available by dialing +1 (617) 801-6888 and entering conference I.D. No. 50840361.

Further information can be obtained by contacting Connie Bienfait at ResMed Inc., San Diego, at +1 (858) 746-2736; Brett Sandercock at ResMed Limited, Sydney, on +1 (612) 8884-2090; or by visiting the Company's multilingual Web site at www.resmed.com.

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company's Web site.

- More -



 
dan.heath
post Posted: Feb 7 2009, 09:47 PM
  Quote Post


Posts: 685
Thanks: 5


In Reply To: Capercat's post @ Feb 6 2009, 10:07 AM

That's the stock market for you, more emotional responses than rational evaluation. How far will it go into the over brought range will it go, is the question .

 
Capercat
post Posted: Feb 6 2009, 10:07 AM
  Quote Post


Posts: 23


Lucky I kept on the sideline rolleyes.gif however the stock overbought IMO

 

sentifi.com

Share Cafe Sentifi Top themes and market attention on:


Capercat
post Posted: Feb 5 2009, 08:14 AM
  Quote Post


Posts: 23


I'm in two minds whether to short this or not. Chart is on the slide, but a good result could boost the stock...

 
dan.heath
post Posted: Jan 31 2009, 07:10 PM
  Quote Post


Posts: 685
Thanks: 5


Hmm... Interest rates likely to go lower, could be big drop, Aussie $ likely to fall , their not reporting early so earnings should be on track, which was up. Cautious US investors maybe be seeking out quality health stocks. I maybe right, make a change, this sp might very well keep going up after earnings announcement. I'll hold a little longer I think. Anyone care to guess what this sp might end up at, for mine I'd reckon $7.50 to $8.00 might see it out.

 
dan.heath
post Posted: Jan 28 2009, 12:46 PM
  Quote Post


Posts: 685
Thanks: 5


This one's sp been heading north for a while now , US investors, are they investing in quality health stocks? How far for how long is the question.Will they continue to invest after upcoming earnings announcement? In my opinion, in this financial climate, they might.
RESMED TO WEBCAST SECOND QUARTER 2009

EARNINGS CONFERENCE CALL

Sydney, Australia, January 27, 2009 -- RESMED INC. (ASX: RMD), announced today that on Friday, February 6, 2009, it will release its earnings for the second quarter of fiscal year 2009, ended December 31, 2008. ResMed will issue an earnings press release after 8.00 a.m. Australian Eastern Daylight Time (AEDT) and will host a conference call to review its quarterly results, market trends, and future outlook.

The conference call is scheduled to begin at 8.30 a.m. Australian Eastern Daylight Time (AEDT) and will be webcast on ResMed's website at www.resmed.com. The online archive of the broadcast will be available approximately 30 minutes after the live call and will continue to be available for two weeks.

International conference call times will be:

9:30 p.m. London (February 5, 2009)

1.30 p.m. San Diego (February 5, 2009)

TO PARTICIPATE in the conference call, please call one of the below numbers at least 10 minutes before the call begins and identify yourself to the operator:

International: +1 617-847-8712

Conference Name: ResMed Inc. 2Q 2009 Earnings Call

Participant Passcode: 28551812

The replay of the conference call will be available approximately 30 minutes after the call and will be accessible for two weeks at:

International: +1 617-801-6888

Passcode: 50840361

ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. Further information can be obtained by contacting Connie Bienfait at ResMed Inc. at +1 (858) 746-2736, or by visiting the Company's Web site at www.resmed.com.



 
dan.heath
post Posted: Nov 12 2008, 09:26 AM
  Quote Post


Posts: 685
Thanks: 5


A little late this post , release a few days old.
QUOTE
RESMED INC ANNOUNCES RECORD FINANCIAL RESULTS FOR THE
QUARTER ENDED SEPTEMBER 30, 2008
SYDNEY, Australia, November 7, 2008 - ResMed Inc. (ASX: RMD) today announced record revenue and
income results for the quarter ended September 30, 2008. Revenue for the quarter was US$217.9 million, a
17% increase over the quarter ended September 30, 2007. For the current quarter, income from operations was
US$36.6 million and net income was US$28.0 million, an increase of 15% and 16%, respectively, compared to
the quarter ended September 30, 2007. Diluted earnings per share for the quarter ended September 30, 2008
was US$0.36, an increase of 16% compared to the quarter ended September 30, 2007.
SG&A costs were US$71.3 million for the quarter, an increase of US$8.5 million or 13% over the same period in
fiscal 2007. The increase in SG&A was primarily due to expenses necessary to support sales growth and the
net appreciation of international currencies against the US dollar. SG&A costs were 33% of revenue in the
September 2008 quarter, compared to 34% in the same period in fiscal 2007.
R&D expenses during the quarter were US$17.3 million, or approximately 8% of revenue. R&D expenses
increased 33% year over year. The increase in research and development outlays reflects ResMed’s continuing
commitment to innovation within its product portfolio, as well as an ongoing commitment to clinical research and
product development. The increase in R&D was also due to the net appreciation of international currencies
against the US dollar.
Amortization of acquired intangibles of US$1.9 million (US$1.3 million net of tax) incurred during the quarter
ended September 30, 2008, consisted of amortization of assets associated with our acquisitions of Resprecare,
Hoefner, Saime and PolarMed. Stock-based compensation costs incurred during the quarter ended September
30, 2008 of US$5.6 million (US$3.9 million net of tax) consisted of expenses associated with stock options
granted to employees and with our employee stock purchase plan.
Inventory, at US$145.6 million, decreased by US$12.7 million compared to June 30, 2008. Accounts receivable
days sales outstanding, at 75 days, increased by 3 days compared to June 30, 2008.
Kieran T. Gallahue, President and Chief Executive Officer, commented, "In the first quarter of fiscal 2009, we
continued to show strong and balanced growth across the globe. Sales outside of the Americas totaled
US$104.3 million, an 18% increase over the prior year quarter, while sales in the Americas were US$113.6
million, an increase of 16% over the prior year quarter. Cash flow from operations for the September quarter was
a record US$67.9 million. Our robust operating cash flows, in addition to our strong and conservative balance
sheet, position us well in the current economic environment.”
Mr. Gallahue continued, “As we move into the second quarter of fiscal 2009, we are well-positioned to grow
revenues. We are encouraged by the sales growth of our S8II flow generator platform and Swift LT nasal pillows
mask. Our new product release schedule remains active, particularly in both the mask and bilevel categories.
We are introducing new masks in both Europe and the US during the second quarter, including the Americas
release of Swift LT for Her. This is the first and only nasal pillows product designed and marketed specifically for
female patients. Additionally, we released a series of new bilevels in Europe and the VPAP S in the Americas.
All of these bilevels utilize our patented Easy-Breathe motor technology, providing unparalleled performance at
up to 90% less noise than other leading competitors. We continue to invest aggressively in developing new
technologies and products to serve the growing sleep-disordered breathing marketplace, while maintaining
prudent fiscal management.”
“Global progress in our efforts to educate and validate the role of sleep-disordered breathing in comorbid patient
populations took a major step forward in the last three months. In September, the European Society of
Cardiologists published guidelines for the diagnosis and treatment of acute and chronic heart failure. For the first
time, the guidelines noted that patients with symptomatic heart failure frequently have sleep-related disorders
(central or obstructive sleep apnea) and recommended treatment with CPAP for patients diagnosed with
obstructive sleep apnea. This follows just three months after the International Diabetes Federation issued a
consensus statement on sleep-disordered breathing and type II diabetes, where the substantial value of
identifying and treating diabetic patients suffering from sleep-disordered breathing was also recognized and
recommended. The increasing awareness among comorbidity specialists augurs well for the efforts and
investment we are making in new markets including diabetes, occupational health and cardiology.”


 
 


9 Pages (Click to Jump) V  < 1 2 3 4 5 6 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING